☰

Shankar Sellappan, Ph.D. - Publications

Affiliations: 
2005 The University of Texas Graduate School of Biomedical Sciences at Houston 
Area:
Cell Biology, Oncology
Tree Info Grants Similar researchers PubMed Report error

10 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2018 Andrali SS, Gordon EM, Reddy SK, Sellappan S, Chang J, Sachdev E, Chawla SP. Genomic and proteomic analysis of patient tumors for molecular target selection. Journal of Clinical Oncology. 36. DOI: 10.1200/Jco.2018.36.15_Suppl.E23567  0.303
2018 Thyparambil SP, Kim YJ, Chambers A, Yan D, SELLAPPAN S, Gong C, Sedgewick A, Newton Y, Sanborn JZ, Vaske CJ, Benz SC, Cecchi F, Kang H, Hembrough TA. Comprehensive proteomic and genomic profiling to identify therapeutic targets in adenoid cystic carcinoma. Journal of Clinical Oncology. 36: 6053-6053. DOI: 10.1200/Jco.2018.36.15_Suppl.6053  0.354
2018 Thyparambil SP, Kim YJ, Chambers AG, Yan D, Sellappan S, Sedgewick AJ, Newton Y, Sanborn JZ, Vaske CJ, Benz SC, Cecchi F, Kang H, Hembrough TA. Abstract 778: Potential drug targets for adenoid cystic carcinoma elucidated by proteogenomic analysis Cancer Research. 78: 778-778. DOI: 10.1158/1538-7445.Am2018-778  0.422
2018 Schwartz S, Heaton R, Tian Y, Sanborn Z, Sellappan S, Cecchi F, Benz S, Hembrough T. Abstract B200: Using “omics” to select immunotherapy and conventional therapy combinations Molecular Cancer Therapeutics. 17. DOI: 10.1158/1535-7163.Targ-17-B200  0.358
2017 Schwartz S, Tian Y, Fasani R, Delgado MD, Hierro C, Rodon J, Sellappan S, Cecchi F, Hembrough T, Nuciforo P. Abstract P6-07-16: Quantitative proteomic analysis of FGFR by mass spectrometry may improve identification of FGFR amplified tumors sensitive to inhibitor therapy Cancer Research. 77. DOI: 10.1158/1538-7445.Sabcs16-P6-07-16  0.435
2017 Sellappan S, Schwartz S, Wertheimer E, Cecchi F, Mamus SW, Catenacci DV, Hembrough T. Abstract 735: HER2 protein quantification in multiple cancer indications identifies candidates for HER2 targeted therapies Cancer Research. 77: 735-735. DOI: 10.1158/1538-7445.Am2017-735  0.504
2006 Efferson CL, Tsuda N, Kawano K, Nistal-Villán E, Sellappan S, Yu D, Murray JL, García-Sastre A, Ioannides CG. Prostate tumor cells infected with a recombinant influenza virus expressing a truncated NS1 protein activate cytolytic CD8+ cells to recognize noninfected tumor cells. Journal of Virology. 80: 383-94. PMID 16352563 DOI: 10.1128/JVI.80.1.383-394.2006  0.565
2004 Sellappan S, Grijalva R, Zhou X, Yang W, Eli MB, Mills GB, Yu D. Lineage infidelity of MDA-MB-435 cells: expression of melanocyte proteins in a breast cancer cell line. Cancer Research. 64: 3479-85. PMID 15150101 DOI: 10.1158/0008-5472.Can-3299-2  0.567
2004 Efferson C, Kawano K, Sellappan S, Yu D, Babaian R, Palese P, Garcia-Sastre A, Ioannides C, Murray J. Prostate Tumor Cells Infected with a Recombinant Influenza Virus with Truncated NS1 Gene NS1 (1-126) Activate Cytolytic CD8+ Cells Which Recognize Non-Infected Tumors Journal of Immunotherapy. 27: S53. DOI: 10.1097/00002371-200411000-00190  0.475
2002 Lee S, Yang W, Lan KH, Sellappan S, Klos K, Hortobagyi G, Hung MC, Yu D. Enhanced sensitization to taxol-induced apoptosis by herceptin pretreatment in ErbB2-overexpressing breast cancer cells. Cancer Research. 62: 5703-10. PMID 12384528  0.493
Show low-probability matches.